Viridian Therapeutics Revenue and Competitors

Boulder, CO USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Viridian Therapeutics's estimated annual revenue is currently $23.4M per year.(i)
  • Viridian Therapeutics's estimated revenue per employee is $125,833

Employee Data

  • Viridian Therapeutics has 186 Employees.(i)
  • Viridian Therapeutics grew their employee count by 51% last year.

Viridian Therapeutics's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Sr. VP, Head ResearchReveal Email/Phone
4
Head Forecasting and Market InsightsReveal Email/Phone
5
Senior Director, Drug DevelopmentReveal Email/Phone
6
Senior Director, Business Development & Strategic AlliancesReveal Email/Phone
7
Senior Director, QCReveal Email/Phone
8
Associate Director Quality ControlReveal Email/Phone
9
Associate DirectorReveal Email/Phone
10
Director, Medical Device QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A29480%N/AN/A
#2
$1.7M110%N/AN/A
#3
$2.8M1813%N/AN/A
#4
$70.2M453-1%N/AN/A
#5
$1.6M10-66%N/AN/A
#6
$3.7M24-8%N/AN/A
#7
$2.9M29-9%N/AN/A
#8
$3.1M2025%N/AN/A
#9
N/A9-10%N/AN/A
#10
$2.5M16-20%N/AN/A
Add Company

What Is Viridian Therapeutics?

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colo., with research and development operations in Waltham, Mass.

keywords:N/A

N/A

Total Funding

186

Number of Employees

$23.4M

Revenue (est)

51%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Viridian Therapeutics News

2022-04-17 - Comparing Sera Prognostics (NASDAQ:SERA) & Viridian ...

This table compares Sera Prognostics and Viridian Therapeutics' revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net...

2022-04-13 - Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of “Buy” by Analysts. Posted by admin on Apr 12th, 2022.

2022-03-30 - Viridian Therapeutics Secures Flexible Credit Facility for Up to ...

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.4M186-10%N/A
#2
$35.9M18732%N/A
#3
$7.5M1907%N/A
#4
$58.5M1976%N/A
#5
$55.7M20010%N/A